These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17125449)

  • 1. Metabolic syndrome treatment strategies.
    Fujioka K
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The obesity epidemic and its cardiovascular consequences.
    Behn A; Ur E
    Curr Opin Cardiol; 2006 Jul; 21(4):353-60. PubMed ID: 16755205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
    Cox SL
    Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 11. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rimonabant actions on cardiometabolic risk factors].
    Stiefelhagen P
    Med Monatsschr Pharm; 2007 Jan; 30(1):39-40. PubMed ID: 17260652
    [No Abstract]   [Full Text] [Related]  

  • 14. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
    Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
    J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hope and fear of rimonabant.
    Rumsfeld JS; Nallamothu BK
    JAMA; 2008 Apr; 299(13):1601-2. PubMed ID: 18387935
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic risk modification: current trends and emerging therapies.
    Lillo JL; Bray G; Woods SC; Henry RR; Hadley RD
    JAAPA; 2006 Dec; Suppl Cardiometabolic():3-14; quiz 15-6. PubMed ID: 17354517
    [No Abstract]   [Full Text] [Related]  

  • 20. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.